New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
NCT ID NCT06908031
First seen Jul 01, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pMMR) and microsatellite stable (MSS). The goal is to see if this combination can make the tumor disappear completely (pathological complete response). The study enrolls 49 adults aged 18-75 with tumors within 10 cm of the anal verge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Short-course radiotherapy, mFOLFOX6 chemotherapy, PD-1 antibody, cetuximab (for RAS/BRAF wild-type), bevacizumab (for RAS/BRAF mutant)
- What this could lead to
- If successful, this combination could offer a more effective, non-surgical treatment path for high-risk rectal cancer, potentially increasing the chance of a complete response.
- What could go wrong
- This is an early-phase trial with only 49 participants, so results may not apply to all patients. Combining multiple therapies raises the risk of severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510065, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a Triple-Drug rechallenge tame colorectal cancer?